OncoMatch/Clinical Trials/NCT06989437
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Is NCT06989437 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies ponsegromab for cachexia.
Treatment: ponsegromab — Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy (nab-paclitaxel, gemcitabine) — first-line
Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy
Must have received: systemic chemotherapy (FOLFIRINOX) — first-line
2 x 14-day cycles of FOLFIRINOX chemotherapy
Lab requirements
Kidney function
Renal disease requiring dialysis or eGFR <30 mL/min/1.73m2 [excluded]
Liver function
Inadequate liver function [excluded]
Cardiac function
Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification; Left ventricular ejection fraction <50% [excluded]
Inadequate liver function; Renal disease requiring dialysis or eGFR <30 mL/min/1.73m2; Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification; Left ventricular ejection fraction <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Kirklin Clinic of UAB Hospital · Birmingham, Alabama
- The University of Alabama at Birmingham · Birmingham, Alabama
- Central Arkansas Radiation Therapy Institute, dba CARTI · Bryant, Arkansas
- Central Arkansas Radiation Therapy Institute, dba CARTI · Conway, Arkansas
- CARTI Cancer Center · Little Rock, Arkansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06989437 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic chemotherapy and systemic chemotherapy.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages